Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $19.96 and last traded at $20.28, with a volume of 110758 shares. The stock had previously closed at $20.24.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the company. Leerink Partners cut IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Stephens reiterated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Wedbush restated an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $53.58.
Check Out Our Latest Stock Report on IDYA
IDEAYA Biosciences Trading Down 1.2 %
The firm's fifty day moving average price is $23.17 and its two-hundred day moving average price is $28.45. The stock has a market capitalization of $1.65 billion, a PE ratio of -5.72 and a beta of 0.82.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On IDEAYA Biosciences
A number of large investors have recently bought and sold shares of the business. Covestor Ltd increased its position in shares of IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after buying an additional 922 shares in the last quarter. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at $35,000. GF Fund Management CO. LTD. acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at $47,000. US Bancorp DE increased its holdings in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after acquiring an additional 689 shares in the last quarter. Finally, KBC Group NV raised its position in IDEAYA Biosciences by 29.1% during the third quarter. KBC Group NV now owns 2,274 shares of the company's stock worth $72,000 after acquiring an additional 513 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.
About IDEAYA Biosciences
(
Get Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Further Reading
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
